Hepatitis C Patients with Cirrhosis in Primary Care Clinics: Implementing Evidence-Based. Guidelines
|
|
- Rodney Byrd
- 6 years ago
- Views:
Transcription
1 Hepatitis C Patients with Cirrhosis in Primary Care Clinics: Implementing Evidence-Based Guidelines Poster Presentation Handout for Scholarly Event March 26, 2013 Michelle M. Lisowski NURS 770: Clinical Scholarship IV Winona State University
2 Educational Items Distributed to Primary Care Providers 1. Clinicians Guide The full text or pdf of this document can be found and downloaded at This document is not copyrighted and users are encouraged to print and distribute as many copies as they need.
3 2. Laminated Pocket Card Cirrhosis Treatment Recommendations HCC surveillance (every 6 months): Ultrasound AFP No varices Part of the Cirrhosis Quicknotes which constitute an abbreviated version of the Management and Treatment of Patients with Cirrhosis and Portal Hypertension (2009), developed by the Department of Veterans Affairs Hepatitis C Resource Center Program. Repeat endoscopy in 3 years (sooner if decompensation occurs) Management of compensated cirrhosis (no ascites, variceal hemorrhage, encephalopathy, or jaundice) Varices surveillance (upper endoscopy) Small varices In a CTP class B or C patient or varices with red signs In a CTP class A patient, without red signs Nonselective betablockers (propranolol or nadolol) Nonselective beta-blockers optional Start propranolol (20 mg BID) or nadolol (40 mg QD) Titrate to maximum tolerable dosage or a heart rate of beats/min No need to repeat endoscopy If no beta-blockers given, repeat endoscopy in 2 years (sooner if decompensation occurs) Medium/Large varices prevention of first variceal hemorrhage Nonselective beta-blockers (propranolol, nadolol) OR Endoscopic variceal ligation (choice depends on patient characteristics and preferences, local resources) Start propranolol (20 mg BID) or nadolol (40 mg QD) Titrate to maximum tolerable dosage or a heart rate of beats/min No need to repeat endoscopy Ligate every 1-2 weeks until variceal obliteration First surveillance endoscopy 1-3 months after obliteration, then every 6-12 months indefinitely
4 3. Hepatocellular Carcinoma Pocket Card from GuidelineCentral.com (Pocket card is copyrighted not able to past to this document) Article on diagnosing cirrhosis sent to providers 1-2 weeks post educational seminar: Udell, J. A., Wang, C. S., Tinmouth, J., FitzGerald, J. M., Ayas, N. T., Simel, D. L.,... Yoshida, E. M. (2012). Does this patient with liver disease have cirrhosis? The Journal of the American Medical Association, 307(8),
5 References Ackley, B. J., Swan, B. A., Ladwig, G., & Tucker, S. (2008). Evidence-based nursing care guidelines: Medical-surgical interventions. St. Louis, Missouri: Mosby Elsevier. Bacon, B. R., O'Grady, J. G., Di Bisceglie, A. M., & Lake, J. R. (2006). Comprehensive clinical hepatology. Philadelpha, Pennsylvania: Mosby. Bruix, J., & Sherman, M. (2005). Management of hepatocellular carcinoma. Hepatology, 42(5), Bruix, J., & Sherman, M. (2011). management of hepatocellular carcinoma: An update. Hepatology, 53(3), doi: /hep Center for Quality Management in Public Health. (2010). The state of care for Veterans with chronic hepatitis C. Palo Alto: U.S. Department of Veteran Affairs, Publich Health Strategic Health Care Group, Center for Quality Management in Public Health. Retrieved from Chou, A. F., Vaughn, T. E., McCoy, K. D., & Doebbeling, B. N. (2011). Implementation of evidence-based practices: Applying a goal commitment framework. Health Care Management Review, 36(1), doi: /hmr.0b013e3181dc8233 Cohen, S. M., & Kataoka-Yahiro, M. (2010). Provider adherence to clinical guidelines related to lipid-lowering medications. Military Medicine, 175, Craig, T. J., Perlin, J. B., & Fleming, B. B. (2007). Self-reported performance improvement strategies of highly successful Veterans Health Administration facilities. American Journal of Medical Quality, 22, doi: / Demakis, J. G., Beauchamp, C., Cull, W. L., Denwood, R., Eisen, S. A., Lofgren, R.,... Henderson, W. G. (2000). Improving residents' compliance with standards of ambulatory care: Results from the VA cooperative study on computerized reminders. Journal of the American Medical Association, 284(11), Flanagan, M. E., Ramanujam, R., & Doebbeling, B. N. (2009). The effect of provider and workflow focused strategies for guideline implementation on provider acceptance. Implementation Science, 4(71), 1. doi: / Garcia-Tsao, G., Sanyal, A. J., Grace, N. D., & Carey, W. (2007). Prevention and management of gastoesophageal varices and variceal hemorrhage in cirrhosis. Hepatology, Goetz, M. B., Hoang, T., Bowman, C., Knapp, H., Rossman, B., Smith, R.,... Asch, S. M. (2008). A system-wide intervention to improve HIV testing in the Veterans Health
6 Administration. Journal of General Internal Medicine, 23(8), doi: /s Grol, R., Wensing, M., Hulscher, M., & Eccles, M. (2005). Theories on implemtation of change in healthcare. In R. Grol, M. Wensing, & M. Eccles, Improving patient care: The implementation of change in clinical practice (pp ). Edinburgh: Elsevier Butterworth Heinemann. Hysong, S. J., Best, R. G., & Pugh, J. A. (2007). Clinical practice guideline implementatin strategy patterns in Veteran Affairs primary care clinics. Health Research and Educational Trust, 42(1), doi: /j x Nouso, K., Tanaka, H., Uematsu, S., Shiraga, K., Okamoto, R., Onishi, H.,... Shiratori, Y. (2008). Cost-effectiveness of the surveillance program of hepatocellular carcinoma depends on the medical circumstances. Hepatology, 23, doi: /j x O'Connor, S., Ward, J. W., Watson, M., Momin, B., & Richardson, L. C. (2010). Hepatocellular Carcinoma---United States, Centers for Disease Contorl and Prevention. Washington, DC: U.S. Government Printing Office. Richardson, W. S., Wilson, M. C., Nishikawa, J., & Hayward, R. S. (1995). The well-built clinical question: A key to evidence-based decision. ACP Journal Club, 123(3), A12- A13. Saleem, J. J., Patterson, E. S., Militello, L., Render, M. L., Orshansky, G., & Asch, S. (2005). Exploring barriers and facilitators to the use of computerized clinical reminders. Journal of the American Medical Informatics Association, 12(4), doi: /jamia.m1777. Schlosser, R. W., Koul, R., & Costello, J. (2007). Asking well-built questions for evidence-based practice in augmentative and alternative communication. Journal of Communication Disorders, 40, doi: /j.jcomdis Spiegel, B. M., Esrailian, E., & Eisen, G. (2007). The budget impact of endoscopic screening for esophageal varices in cirrhosis. Gastrointestinal Endoscopy, 66(4), doi: /j.gie Stetler, C. B., Mittman, B. S., & Francis, J. (2008). Overview of the VA Quality Enhancement Research Initiative (QUERI) and QUERI theme articles: QUERI series. Implementation Science, 3(8), doi: / Stravitz, R. T., Heuman, D. M., Chand, N., Sterling, R. K., Shiffman, M. L., Luketic, V. A.,... Fisher, R. A. (2008). Surveillance for hepatocellular carcinoma in patients with cirrhosis
7 improves outcome. The American Journal of Medicine, 21, doi: /j.amjmed Udell, J. A., Wang, C. S., Tinmouth, J., FitzGerald, J. M., Ayas, N. T., Simel, D. L.,... Yoshida, E. M. (2012). Does this patient with liver disease have cirrhosis? The Journal of the American Medical Association, 307(8), Xu, J., Kochanek, K. D., Murphy, S. L., & Tejada-Vera, B. (2010). Deaths: Final data for National Vital Statistics Reports, 58(19), 1-73.
ACG & AASLD Joint Clinical Guideline: Prevention and Management of Gastroesophageal Varices and Variceal Hemorrhage in Cirrhosis
ACG & AASLD Joint Clinical Guideline: Prevention and Management of Gastroesophageal Varices and Variceal Hemorrhage in Cirrhosis Guadalupe Garcia-Tsao, M.D., 1 Arun J. Sanyal, M.D., 2 Norman D. Grace,
More informationEsophageal Varices Beta-Blockers or Band Ligation. Cesar Yaghi MD Hotel-Dieu de France University Hospital Universite Saint Joseph
Esophageal Varices Beta-Blockers or Band Ligation Cesar Yaghi MD Hotel-Dieu de France University Hospital Universite Saint Joseph Esophageal Varices Beta-Blockers or Band Ligation? Risk of esophageal variceal
More informationDISCLOSURES. This activity is jointly provided by Northwest Portland Area Indian Health Board and Cardea
DISCLOSURES This activity is jointly provided by Northwest Portland Area Indian Health Board and Cardea Cardea Services is approved as a provider of continuing nursing education by Montana Nurses Association,
More informationCauses of Liver Disease in US
Learning Objectives Updates in Outpatient Cirrhosis Management Jennifer Guy, MD MAS Director, Liver Cancer Program California Pacific Medical Center guyj@sutterhealth.org Review cirrhosis epidemiology,
More informationVariceal bleeding. Mainz,
Variceal bleeding Mainz, 21.09.2008 Risk of complications 5 years 10 years Ascites 10 % 25 % HCC 10 % 25 % Bleeding < 5 % 5-10 % Enceph. < 5 % < 5 % Typical situation : Mortality 10 % to 40 % Sequence
More informationLearning Objectives. After attending this presentation, participants will be able to:
Learning Objectives After attending this presentation, participants will be able to: Describe HCV in 2015 Describe how to diagnose advanced liver disease and cirrhosis Identify the clinical presentation
More informationSteps in Assessing Fibrosis 4/30/2015. Overview of Liver Disease Associated With HCV
Overview of Liver Disease Associated With HCV Marion G. Peters, MD John V. Carbone, Endowed Chair Professor of Medicine Chief of Hepatology Research University of California San Francisco San Francisco,
More informationCLINICAL How Should a Hospitalized Patient with Newly Diagnosed Cirrhosis Be Evaluated and Managed?
CLINICAL How Should a Hospitalized Patient with Newly Diagnosed Cirrhosis Be Evaluated and Managed? The Hospitalist. 2016 August;2016(8) Author(s): Raj Sehgal, MD; Joshua Hanson, MD, MPH; Division OF The
More informationESLD a Guide for HIV Physicians. Marion Peters University of California San Francisco June 2015
ESLD a Guide for HIV Physicians Marion Peters University of California San Francisco June 2015 Disclosures Honararia from Johnson and Johnson Roche Merck Gilead Spouse employee of Hoffman La Roche Natural
More informationEnd-Stage Liver Disease (ESLD): A Guide for HIV Physicians
Slide 1 of 32 End-Stage Liver Disease (ESLD): A Guide for HIV Physicians Marion G. Peters, MD John V. Carbone, MD, Endowed Chair Professor of Medicine Chief of Hepatology Research University of California
More informationValidation of Clinical Outcomes in Electronic Data Sources
Validation of Clinical Outcomes in Electronic Data Sources Vincent Lo Re, MD, MSCE Assistant Professor of Medicine and Epidemiology Center for Clinical Epidemiology and Biostatistics Center for Pharmacoepidemiology
More informationMichele Bettinelli RN CCRN Lahey Health and Medical Center
Michele Bettinelli RN CCRN Lahey Health and Medical Center Differentiate the types of varices Identify glue preparations utilized when treating gastric varices Review the process of glue administration
More informationEvidence-Base Management of Esophageal and Gastric Varices
Evidence-Base Management of Esophageal and Gastric Varices Rino Alvani Gani Hepatobiliary Division Department of Internal Medicine Faculty of Medicine Universitas Indonesia Cipto Mangunkusumo National
More informationAre we adequately screening at-risk patients for hepatocellular carcinoma in the outpatient setting?
Rajani Sharma, PGY1 Geriatrics CRC Project, 12/19/13 Are we adequately screening at-risk patients for hepatocellular carcinoma in the outpatient setting? A. Study Purpose and Rationale Hepatocellular carcinoma
More informationCare of the Patient With Cirrhosis
REVIEW Care of the Patient With Cirrhosis Anitha Yadav, M.D., and Hugo E. Vargas, M.D. Caring for patients with cirrhosis involves multidisciplinary and timely management of several complications while
More informationPrimary Prophylaxis against Variceal Hemorrhage Pharmacotherapy vs Endoscopic Band Ligation
Primary Prophylaxis against Variceal Hemorrhage Pharmacotherapy vs Endoscopic Band Ligation Siwaporn Chainuvati, MD Faculty of Medicine Siriraj Hospital Outline Natural history of esophageal varices Which
More informationCarvedilol or Propranolol in the Management of Portal Hypertension?
Evidence Based Case Report Carvedilol or Propranolol in the Management of Portal Hypertension? Arranged by: dr. Saskia Aziza Nursyirwan RESIDENCY PROGRAM OF INTERNAL MEDICINE DEPARTMENT UNIVERSITY OF INDONESIA
More informationCIRRHOSIS Definition
Cirrhosis Update Robert S. Brown, Jr., MD, MPH Vice Chair, Transitions of Care Interim Chief, Division of Gastroenterology & Hepatology Weill Cornell Medical College CIRRHOSIS Definition Irreversible fibrous
More informationHepatitis Alert: Management of Patients With HCV Who Have Achieved SVR
Hepatitis Alert: Management of Patients With HCV Who Have Achieved SVR This program is supported by educational grants from AbbVie, Gilead Sciences, and Merck About These Slides Please feel free to use,
More informationIndex. Note: Page numbers of article titles are in boldface type.
Index Note: Page numbers of article titles are in boldface type. A Acute variceal bleeding management of, 251 262 balloon tamponade of esophagus in, 257 258 endoscopic therapies in, 255 257. See also Endoscopy,
More informationHepatitis and pregnancy
Hepatitis and pregnancy Pierre-Jean Malè MD Training Course in Reproductive Health Research WHO Geneva 2008 26.02.2008 Liver disease and pregnancy: three possible etiologic relationship the patient has
More informationModule 1 Introduction of hepatitis
Module 1 Introduction of hepatitis 1 Training Objectives At the end of the module, trainees will be able to ; Demonstrate improved knowledge of the global epidemiology of the viral hepatitis Understand
More informationORIGINAL ARTICLES LIVER, PANCREAS, AND BILIARY TRACT
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2010;8:703 708 ORIGINAL ARTICLES LIVER, PANCREAS, AND BILIARY TRACT Compliance With Practice Guidelines and Risk of a First Esophageal Variceal Hemorrhage in Patients
More informationEmricasan (IDN-6556) administered orally for 28 days lowers portal pressure in patients with compensated cirrhosis and severe portal hypertension
Emricasan (IDN-6556) administered orally for 28 days lowers portal pressure in patients with compensated cirrhosis and severe portal hypertension Guadalupe Garcia-Tsao, Michael Fuchs, Mitchell Shiffman,
More informationControversies in Management of Portal Hypertension and Cirrhosis Complications in the Transplant Candidate
Controversies in Management of Portal Hypertension and Cirrhosis Complications in the Transplant Candidate Patrick Northup, MD, FAASLD, FACG Medical Director, Liver Transplantation University of Virginia
More informationConflict of interest disclosures. Complications of end stage liver disease. None. The many complications of Cirrhosis. Portal Hypertension.
Complications of end stage liver disease Conflict of interest disclosures None Amir Qamar, MD Instructor of Medicine Brigham and Women s s Hospital Harvard Medical School Boston, MA 02115 The many complications
More informationChronic liver disease generally
Preventive Strategies in Chronic Liver Disease: Part II. Cirrhosis THOMAS R. RILEY III, M.D., M.S., and AHSAN M. BHATTI, M.D. Pennsylvania State University College of Medicine, Hershey, Pennsylvania Cirrhosis
More information3 Workshop on HCV THERAPY ADVANCES New Antivirals in Clinical Practice
3 Workshop on HCV THERAPY ADVANCES New Antivirals in Clinical Practice Rome, 13 December 2013 Management and monitoring of HCC in the future era of DAA s Prof. Massimo Colombo Chairman Department of Liver,
More informationLife After SVR for Cirrhotic HCV
Life After SVR for Cirrhotic HCV KIM NEWNHAM MN, NP CIRRHOSIS CARE CLINIC UNIVERSITY OF ALBERTA Objectives To review the benefits of HCV clearance in cirrhotic patients To review some of the emerging data
More informationCOMPLICATIONS OF CIRRHOSIS: ASCITES & HEPATIC ENCEPHALOPATHY
COMPLICATIONS OF CIRRHOSIS: ASCITES & HEPATIC ENCEPHALOPATHY DR. ESTER YAGUDAYEVA CLINICAL PHARMACIST HOSPICE PHARMACY SOLUTIONS OBJECTIVES Understand the prognosis of End Stage Liver Disease (ESLD) Identify
More informationDr. John C Rwegasha.FRCP(Lond),MSc, Muhimbili National Hospital Dar es Salaam Tanzania 15/09/2018 1
Dr. John C Rwegasha.FRCP(Lond),MSc, Muhimbili National Hospital Dar es Salaam Tanzania 15/09/2018 1 No disclosures. 15/09/2018 2 Sub-Saharan Africa (SSA) has a high burden of morbidity and mortality resulting
More informationCost-effectiveness of hepatic venous pressure gradient measurements for prophylaxis of variceal re-bleeding Raines D L, Dupont A W, Arguedas M R
Cost-effectiveness of hepatic venous pressure gradient measurements for prophylaxis of variceal re-bleeding Raines D L, Dupont A W, Arguedas M R Record Status This is a critical abstract of an economic
More informationIs pharmacological therapy the best choice for primary prevention of variceal hemmorhaging in patients with hepatic cirrhosis?
Controversies en Gastroenterology Is pharmacological therapy the best choice for primary prevention of variceal hemmorhaging in patients with hepatic cirrhosis? Rolando José Ortega Quiroz, MD, 1 Adalgiza
More informationGI bleeding in chronic liver disease
GI bleeding in chronic liver disease Stuart McPherson Consultant Hepatologist Liver Unit, Freeman Hospital, Newcastle upon Tyne and Institute of Cellular Medicine, Newcastle University. Case 54 year old
More informationCase Report: Refractory variceal bleeding Christophe Hézode, Henri Mondor Hospital, Paris-Est University, Créteil, France
Case Report: Refractory variceal bleeding Christophe Hézode, Henri Mondor Hospital, Paris-Est University, Créteil, France Thank you to Marika Rudler, Dominique Thabut, Adrian Gadano, and Jaime Bosch for
More informationCirrhosis the end stage of chronic liver disease characterized
Suzanne E. Minor, MD, FAAFP; Irmanie Eliacin, MD; Sanaz Kashan, MD; Ebony B. Whisenant, MD Florida International University, Herbert Wertheim College of Medicine, Miami seminor@fiu.edu The authors reported
More informationEnd Stage Liver Disease & Disease Specific Indications for Liver Transplant. Susan Kang, RN, MSN, ANP-BC
End Stage Liver Disease & Disease Specific Indications for Liver Transplant Susan Kang, RN, MSN, ANP-BC Introduction (https://www.srtr.org) What does the liver do? STORAGE METABOLIC DETOXIFICATION SYNTHETIC
More informationEnd Stage Liver Disease & Disease Specific Indications for Liver Transplant Susan Kang, RN, MSN, ANP BC
End Stage Liver Disease & Disease Specific Indications for Liver Transplant Susan Kang, RN, MSN, ANP BC Introduction (https://www.srtr.org) 1 What does the liver do? STORAGE METABOLIC DETOXIFICATION SYNTHETIC
More informationISR Process for Internal Service Providers
ISR Process for Internal Service Providers Course Outline 1) Internal Service Request Process Overview Internal Service Requests (ISR) are created by the end user via the BUworks Central Portal Procurement
More informationOntario s Adult Referral and Listing Criteria for Liver Transplantation
Ontario s Adult Referral and Listing Criteria for Liver Transplantation Version 3.0 Trillium Gift of Life Network Ontario s Adult Referral & Listing Criteria for Liver Transplantation PATIENT REFERRAL
More informationVirtual Mentor American Medical Association Journal of Ethics December 2008, Volume 10, Number 12:
Virtual Mentor American Medical Association Journal of Ethics December 2008, Volume 10, Number 12: 805-809. CLINICAL PEARL Indications for Use of TIPS in Treating Portal Hypertension Elizabeth C. Verna,
More informationENCORE-PH Top-line Results
ENCORE-PH Top-line Results Striving to improve human health December 5, 2018 NASDAQ CNAT Forward-looking Statements This presentation contains forward-looking statements. All statements other than statements
More informationThe Continuum of Care for Advanced Liver Disease: Partnering with the Liver Specialist. K V Speeg, MD, PhD UT Health San Antonio
The Continuum of Care for Advanced Liver Disease: Partnering with the Liver Specialist K V Speeg, MD, PhD UT Health San Antonio Objectives Review staging of liver disease Review consequences of end-stage
More informationEvaluating HIV Patient for Liver Transplantation. Marion G. Peters, MD Professor of Medicine University of California San Francisco USA
Evaluating HIV Patient for Liver Transplantation Marion G. Peters, MD Professor of Medicine University of California San Francisco USA Slide 2 ESLD and HIV Liver disease has become a major cause of death
More informationREVIEW. Ariel W. Aday, M.D.,* Nicole E. Rich, M.D.,* Arjmand R. Mufti, M.D., and Shannan R. Tujios, M.D.
REVIEW CON ( The Window Is Closed ): In Patients With Cirrhosis With Ascites, the Clinical Risks of Nonselective beta-blocker Outweigh the Benefits and Should NOT Be Prescribed Ariel W. Aday, M.D.,* Nicole
More informationCost-effectiveness analysis of beta-blockers vs endoscopic surveillance in patients with cirrhosis and small varices
Submit a Manuscript: http://www.wjgnet.com/esps/ Help Desk: http://www.wjgnet.com/esps/helpdesk.aspx DOI: 10.3748/wjg.v20.i30.10464 World J Gastroenterol 2014 August 14; 20(30): 10464-10469 ISSN 1007-9327
More informationHepatocellular Carcinoma: Diagnosis and Management
Hepatocellular Carcinoma: Diagnosis and Management Nizar A. Mukhtar, MD Co-director, SMC Liver Tumor Board April 30, 2016 1 Objectives Review screening/surveillance guidelines Discuss diagnostic algorithm
More informationDISCLOSURES. This activity is jointly provided by Northwest Portland Area Indian Health Board and Cardea
DISCLOSURES This activity is jointly provided by Northwest Portland Area Indian Health Board and Cardea Cardea Services is approved as a provider of continuing nursing education by Montana Nurses Association,
More informationOutreach Invitations Improve HCC Surveillance Rates: Results Of A Randomized Controlled Trial
Outreach Invitations Improve HCC Surveillance Rates: Results Of A Randomized Controlled Trial Amit G. Singal MD MS UT Southwestern Medical Center and Parkland Health & Hospital System Dallas, TX, USA 1
More informationBeta-blockers in cirrhosis: Cons
Beta-blockers in cirrhosis: Cons Eric Trépo MD, PhD Dept. of Gastroenterology. Hepatopancreatology and Digestive Oncology. C.U.B. Hôpital Erasme. Université Libre de Bruxelles. Bruxelles. Belgium Laboratory
More informationPaul Martin MD FACG. University of Miami
Paul Martin MD FACG University of Miami 1 Liver cirrhosis of any cause Chronic C o c hepatitis epat t s B Risk increases with Male gender Age Diabetes Smoking ~5% increase in HCV-related HCC between 1991-28
More informationHepatitis C Medications Hawaii PRIOR AUTHORIZATION REQUEST FORM
Please complete this entire form and fax it to: 866-940-7328. If you have questions, please call 800-310-6826. This form contains multiple pages. Please complete all pages to avoid a delay in our decision.
More informationHCV care after cure. This program is supported by educational grants from
HCV care after cure This program is supported by educational grants from Raffaele Bruno,MD Department of Infectious Diseases, Hepatology Outpatients Unit University of Pavia Fondazione IRCCS Policlinico
More informationEditorial Process: Submission:07/25/2018 Acceptance:10/19/2018
RESEARCH ARTICLE Editorial Process: Submission:07/25/2018 Acceptance:10/19/2018 Clinical Outcome and Predictive Factors of Variceal Bleeding in Patients with Hepatocellular Carcinoma in Thailand Jitrapa
More informationDetection of Esophageal Varices Using CT and MRI
Dig Dis Sci (2011) 56:2696 2700 DOI 10.1007/s10620-011-1660-8 ORIGINAL ARTICLE Detection of Esophageal Varices Using CT and MRI Michael J. Lipp Arkady Broder David Hudesman Pauline Suwandhi Steven A. Okon
More informationMedical Necessity Guidelines: Upper GI Endoscopy: Certain Elective Procedures
Medical Necessity Guidelines: Upper GI Endoscopy: Certain Elective Procedures Effective: October 11, 2017 Clinical documentation and prior authorization required Coverage guideline, no prior authorization
More informationth Annual AISF Meeting 44 th th th, 2011 Rome, February 23 rd -26
44 th 44 th Annual AISF Meeting Rome, February 23 rd -26 th th, 2011 Update on the Baveno Consensus Conference Roberto de Franchis Department of of Clinical Sciences, University of of Milan, Head, Gastroenterology
More informationMeet the Professor: HIV/HCV Coinfection
Meet the Professor: HIV/HCV Coinfection Vincent Lo Re, MD, MSCE Assistant Professor of Medicine and Epidemiology Division of Infectious Diseases Center for Clinical Epidemiology and Biostatistics University
More informationHepatitis C Policy Discussion
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationHepatology For The Nonhepatologist
Hepatology For The Nonhepatologist Andrew Aronsohn, MD Associate Professor of Medicine University of Chicago Chicago, Illinois Learning Objectives After attending this presentation, learners will be able
More informationSurveillance for HCC Who, how Diagnosis of HCC Surveillance for HCC in Practice
Surveillance for Hepatocellular Carcinoma Hashem B. El-Serag, MD, MPH Dan L. Duncan Professor of Medicine Chief, Gastroenterology and Hepatology Houston VA & Baylor College of Medicine Houston, TX Outline
More informationNONSELECTIVE BETA-BLOCKERS IN PATIENTS WITH CIRRHOSIS: THE THERAPEUTIC WINDOW
Rev. Med. Chir. Soc. Med. Nat., Iaşi 2016 vol. 120, no. 1 INTERNAL MEDICINE UPDATES NONSELECTIVE BETA-BLOCKERS IN PATIENTS WITH CIRRHOSIS: THE THERAPEUTIC WINDOW Mihaela Dimache 1,2*, Irina Gîrleanu 1,2,
More informationIS THERE A DIFFERENCE IN LIVER CANCER RATES IN PATIENTS WHO RECEIVE TREATMENT FOR HEPATITIS?
IS THERE A DIFFERENCE IN LIVER CANCER RATES IN PATIENTS WHO RECEIVE TREATMENT FOR HEPATITIS? Dr. Sammy Saab David Geffen School of Medicine, Los Angeles, USA April 2018 DISCLAIMER Please note: The views
More informationStick or twist management options in hepatitis C
Stick or twist management options in hepatitis C Dr. Chris Durojaiye & Dr. Matthijs Backx SpR Microbiology and Infectious Diseases University Hospital of Wales, Cardiff Patient history 63 year old female
More informationTitle: The Baveno VI criteria for predicting esophageal varices: validation in real life practice
Title: The Baveno VI criteria for predicting esophageal varices: validation in real life practice Authors: Mafalda Sousa, Sónia Fernandes, Luísa Proença, Ana Paula Silva, Sónia Leite, Joana Silva, Ana
More information2.0 Synopsis. Ombitasvir/Paritaprevir/Ritonavir, Dasabuvir, RBV M Clinical Study Report R&D/16/1328. (For National Authority Use Only)
2.0 Synopsis AbbVie Inc. Name of Study Drug: ombitasvir (OBV), paritaprevir (PTV), ritonavir (r), dasabuvir (DSV), ribavirin (RBV) Name of Active Ingredient: ombitasvir: Dimethyl ([(2S,5S)-1-(4-tert- butylphenyl)pyrrolidine-2,5-
More informationPrimary Care Approach to Diagnosis and Management of Chronic Hepatitis C Brian Viviano, D.O.
Primary Care Approach to Diagnosis and Management of Chronic Hepatitis C Brian Viviano, D.O. Objectives Epidemiology of chronic hepatitis C CDC guidelines on screening or hepatitis C Diagnosing hepatitis
More informationThe validity of viral hepatitis and chronic liver disease diagnoses in Veterans Affairs administrative databases
Alimentary Pharmacology & Therapeutics The validity of viral hepatitis and chronic liver disease diagnoses in Veterans Affairs administrative databases J. R. KRAMER*,, J.A.DAVILA*,, E.D.MILLER*,, P.RICHARDSON*,,
More informationEuropean. Young Hepatologists Workshop. Organized by : Quantification of fibrosis and cirrhosis outcomes
supported by from Gilea Quantification of fibrosis and cirrhosis outcomes th 5 European 5 European Young Hepatologists Workshop Young Hepatologists Workshop August, 27-29. 2015, Moulin de Vernègues Vincenza
More informationENDOSCOPIC LIGATION OF ESOPHAGEAL VARICES LONG TERM RESULTS
ENDOSCOPIC LIGATION OF ESOPHAGEAL VARICES LONG TERM RESULTS R. Nikolov, St.Ivan Rilski University Hospital, Clinic of Gastroenterology Sofia, Bulgaria, Medical University Sofia, Bulgaria Contact: R. Nikolov,
More informationLiver disease in 2017: challenges and opportunities
Liver disease in 2017: challenges and opportunities Dr Matthew Cowan Consultant Gastroenterologist and Hepatologist Surrey and Sussex Healthcare NHS Trust Faculty of Physician Associates 2 nd National
More informationCirrhosis and Portal Hypertension Gastroenterology Teaching Project American Gastroenterological Association
CIRRHOSIS AND PORTAL HYPERTENSION Cirrhosis and Portal Hypertension Gastroenterology Teaching Project American Gastroenterological Association WHAT IS CIRRHOSIS? What is Cirrhosis? DEFINITION OF CIRRHOSIS
More informationClinical Trials & Endpoints in NASH Cirrhosis
Clinical Trials & Endpoints in NASH Cirrhosis April 25, 2018 Peter G. Traber, MD CEO & CMO, Galectin Therapeutics 2018 Galectin Therapeutics NASDAQ: GALT For more information, see galectintherapeutics.com
More informationA. Purpose and Scope of the Guidance PRACTICE GUIDANCE HEPATOLOGY, VOL. 65, NO. 1, 2017
AMERICAN ASSOCIATION FOR THE STUDY OFLIVERD I S E ASES PRACTICE GUIDANCE HEPATOLOGY, VOL. 65, NO. 1, 2017 Portal Hypertensive Bleeding in Cirrhosis: Risk Stratification, Diagnosis, and Management: 2016
More informationORIGINAL ARTICLES LIVER, PANCREAS AND BILIARY TRACT
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2008;6:1129 1134 ORIGINAL ARTICLES LIVER, PANCREAS AND BILIARY TRACT Spleen Enlargement on Follow-Up Evaluation: A Noninvasive Predictor of Complications of Portal
More informationBeta-Blockers to Prevent Gastroesophageal Varices in Patients with Cirrhosis
The new england journal of medicine original article Beta-Blockers to Prevent Gastroesophageal Varices in Patients with Cirrhosis Roberto J. Groszmann, M.D., Guadalupe Garcia-Tsao, M.D., Jaime Bosch, M.D.,
More informationMonitoring Patients Who Are Starting HCV Treatment, Are On Treatment, Or Have Completed Therapy
Monitoring Patients Who Are Starting HCV Treatment, Are On Treatment, Or Have Completed Therapy WV ECHO August 10, 2017 Selection of patients for HCV treatment Despite current guidance to treat everyone,
More informationPROGRAMME AT A GLANCE
PROGRAMME AT A GLANCE Hotel Hyatt Andaz Hotel Pullman Date Hall-H1 Hall-H2 Hall-P1 Hall-P2 Hall-P3 Hall-P4 Hall-P5 Hall-P6 Basic science workshop 1 Basic Science Workshop 2 Postgraduate Course - Liver
More informationDISEASE LEVEL MEDICAL EVIDENCE PROTOCOL
DISEASE LEVEL MEDICAL EVIDENCE PROTOCOL 1. This Protocol sets out the medical evidence that must be delivered to the Administrator for proof of Disease Level. It is subject to such further and other Protocols
More informationHepatocellular Carcinoma: Epidemiology and Screening
Hepatocellular Carcinoma: Epidemiology and Screening W. Ray Kim, MD Professor and Chief Gastroenterology and Hepatology Stanford University School of Medicine Case A 67 year old Filipino-American woman
More informationHCC Screening Compliance Module: A Tool for Automated Compliance Monitoring, Clinician Notification, and Efficacy Research
SIIM 2017 Scientific Session Quality & Performance Improvement Part 2 Friday, June 2 7:00 am 8:00 am HCC Screening Compliance Module: A Tool for Automated Compliance Monitoring, Clinician Notification,
More informationHIV/AIDS DEPARTMENT GLOBAL HEPATITIS PROGRAMME
HIV/AIDS DEPARTMENT GLOBAL HEPATITIS PROGRAMME Technical considerations and case definitions for VIRAL HEPATITIS SURVEILLANCE Dr Yvan J-F Hutin Global Hepatitis Programme 01 FOUR MAIN HEPATITIS VIRUSES
More informationHepatitis C Virus (HCV)
Clinical Practice Guidelines Hepatitis C Virus (HCV) OBJECTIVE The purpose is to guide the appropriate diagnosis and management of Hepatitis C Virus (HCV). GUIDELINE These are only guidelines, and are
More informationSurveillance for Hepatocellular Carcinoma
Surveillance for Hepatocellular Carcinoma Marion G. Peters, MD John V. Carbone, MD, Endowed Chair Professor of Medicine Chief of Hepatology Research University of California San Francisco Recorded on April
More informationIndex. Note: Page numbers of article titles are in boldface type.
Index Note: Page numbers of article titles are in boldface type. A ACLF. See Acute-on-chronic liver failure (ACLF) Acute kidney injury (AKI) in ACLF patients, 967 Acute liver failure (ALF), 957 964 causes
More informationMANAGEMENT OF LIVER CIRRHOSIS: PRACTICE ESSENTIALS AND PATIENT SELF-MANAGEMENT
MANAGEMENT OF LIVER CIRRHOSIS: PRACTICE ESSENTIALS AND PATIENT SELF-MANAGEMENT Sherona Bau, ACNP The Pfleger Liver Institute 200 UCLA Medical Plaza, Suite 214 Los Angeles, CA 90095 September 30, 2017 I
More informationFaculty Disclosure. Objectives. Cirrhosis Management for the Family Physician 18/11/2014
Cirrhosis Management for the Family Physician Mang Ma, MD, FRCP Professor University of Alberta Faculty: Mang Ma Faculty Disclosure Relationships with commercial interests: Advisory Board: Merck, Gilead
More informationSandipan Ghose, Md. Azizul Hoque, Md. Khalilur Rahman, Mohd. Harun-or-Rashid
Sandipan Ghose, Md. Azizul Hoque, Md. Khalilur Rahman, Mohd. Harun-or-Rashid Liver cirrhosis may be defined as a diffuse process characterized by fibrosis and conversion of normal liver architecture into
More informationCURRICULUM VITAE. Iliana Simeonova Bouneva, MD
CURRICULUM VITAE Iliana Simeonova Bouneva, MD Date updated: November 10, 2009 Place of birth: Petrovo, Bulgaria Citizenship: USA (permanent resident) Medical Licensure: Virginia License Date of license:
More informationManagement of Ascites and Hepatorenal Syndrome. Florence Wong University of Toronto. June 4, /16/ Gore & Associates: Consultancy
Management of Ascites and Hepatorenal Syndrome Florence Wong University of Toronto June 4, 2016 6/16/2016 1 Disclosures Gore & Associates: Consultancy Sequana Medical: Research Funding Mallinckrodt Pharmaceutical:
More informationIs exposure to Agent Orange a risk factor for hepatocellular cancer? A single-center retrospective study in the U.S. veteran population
Original Article Is exposure to Agent Orange a risk factor for hepatocellular cancer? A single-center retrospective study in the U.S. veteran population Padmini Krishnamurthy, Nyla Hazratjee, Dan Opris,
More informationEvaluation and Prognosis of Patients with Cirrhosis
Hepatitis C Online PDF created October 31, 2018, 1:57 pm Evaluation and Prognosis of Patients with Cirrhosis This is a PDF version of the following document: Section 2: Evaluation, Staging, and Monitoring
More informationHepatocellular Carcinoma Surveillance
Amit G. Singal, MD, MS Hepatocellular Carcinoma Surveillance Postgraduate Course: Challenges in Management of Common Liver Diseases 308 1 Patient Case 69 year-old otherwise healthy male with compensated
More informationHepatology for the Nonhepatologist
Hepatology for the Nonhepatologist Kenneth E. Sherman, MD, PhD Gould Professor of Medicine Director, Division of Digestive Diseases University of Cincinnati College of Medicine Cincinnati, Ohio Learning
More informationDENOMINATOR: All patients aged 18 years and older with a diagnosis of chronic hepatitis C cirrhosis
Quality ID #401: Hepatitis C: Screening for Hepatocellular Carcinoma (HCC) in Patients with Cirrhosis National Quality Strategy Domain: Effective Clinical Care 2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY
More informationScreening for hepatocellular carcinoma (HCC) is controversial.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2007;5:508 512 Screening for Hepatocellular Carcinoma Among Veterans With Hepatitis C on Disease Stage, Treatment Received, and Survival LUCI K. LEYKUM,* HASHEM
More informationNatural history of α-1-atd in children
Natural history of α-1-atd in children Agnieszka Bakuła Dpt of Gastroenterology, Hepatology, Nutrition Disorders and Paediatrics The Children s Memorial Health Institute Warsaw, Poland Topics to be discussed
More informationWorldwide Causes of HCC
Approach to HCV Treatment in Patients with HCC Mark W. Russo, MD, MPH, FACG Carolinas HealthCare System Charlotte Worldwide Causes of HCC 60% 50% 40% 30% 20% 10% 0% 54% 31% 15% Hepatitis B Hepatitis C
More informationBETA-BLOCKERS IN CIRRHOSIS.PRO.
BETA-BLOCKERS IN CIRRHOSIS.PRO. Angela Puente Sánchez. MD PhD Hepatology Unit. Gastroenterology department Marques de Valdecilla University Hospital. Santander INTRODUCTION. Natural history of cirrhosis
More information